Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

09-11-2020 | ACR 2020 | Conference coverage | Video

Trial suggests no benefit of tocilizumab for COVID-19

John Stone talks about the BACC Bay Tocilizumab Trial, which demonstrated similar outcomes among hospitalized COVID-19 patients treated with the IL-6 inhibitor versus placebo in addition to standard care (6:47).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read transcript

Related content

22-10-2020 | COVID-19 | News

Early RCT evidence suggests tocilizumab may not be beneficial for COVID-19

28-08-2020 | COVID-19 | News

Tocilizumab associated with improved outcomes in patients with COVID-19

17-04-2020 | COVID-19 | News

Tocilizumab potential for COVID-19 suggested

29-06-2020 | COVID-19 | News

COVID-19: Support for further investigation of tocilizumab
Image Credits